Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

Delayed Quote. Delayed  - 02/12 03:59:58 pm
47.47 USD   +3.26%
02/03 OPHTHOTECH : to Present at the LEERINK Partners 5th Annual Global He..
02/01 OPHTHOTECH : International Drug Development Institute Partners with ..
02/01 OPHTHOTECH : International Drug Development Institute Enters into Re..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Ophthotech : to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

02/03/2016 | 07:30am US/Eastern

- Webcast Available Through Ophthotech Website -

Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the LEERINK Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:05 a.m. Eastern Time.

Investors and the general public are invited to listen to a live webcast of the presentation at www.ophthotech.com. Please connect to Ophthotech’s website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay will be available for 14 days following the presentation.

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients to potentially reduce the treatment burden. For more information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.

OPHT-G


© Business Wire 2016
React to this article
Latest news on OPHTHOTECH CORP
02/03 OPHTHOTECH : to Present at the LEERINK Partners 5th Annual Global Healthcare Con..
02/01 OPHTHOTECH : International Drug Development Institute Partners with Ophthotech
02/01 OPHTHOTECH : International Drug Development Institute Enters into Research Agree..
01/27 OPHTHOTECH : Announces First Patient Dosed in Zimura® Phase 2/3 Study to Evaluat..
01/14 OPHTHOTECH : Announces Appointment of David E. Redlick to Its Board of Directors
01/06 OPHTHOTECH : Announces Appointment of David E. Redlick to Its Board of Directors
01/06 OPHTHOTECH : Announces Appointment of David E. Redlick to Its Board of Directors
01/05 OPHTHOTECH : Change in Directors or Principal Officers (form 8-K)
01/05 OPHTHOTECH : Glenn P. Sblendorio to Join Ophthotech as Executive Vice President,..
01/04 OPHTHOTECH : to Present at the 34th Annual J.P. Morgan Healthcare Conference
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials